[1]
|
Bray, F., Ferlay, J., Soerjomataram, I., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424.
https://doi.org/10.3322/caac.21492
|
[2]
|
Jeselsohn, R. (2017) Are We Ready to Use ESR1 Mutations in Clinical Practice? Breast Care (Basel), 12, 309-313.
https://doi.org/10.1159/000481428
|
[3]
|
Castellano, I., Chiusa, L., Vandone, A.M., et al. (2013) A Simple and Re-producible Prognostic Index in Luminal ER-Positive Breast Cancers. Annals of Oncology, 24, 2292-2297. https://doi.org/10.1093/annonc/mdt183
|
[4]
|
Chen, T., Liu, Z., Zeng, W., et al. (2019) Down-Regulation of Long Non-Coding RNA HOTAIR Sensitizes Breast Cancer to Trastuzumab. Scientific Reports, 9, Article No. 19881. https://doi.org/10.1038/s41598-019-53699-w
|
[5]
|
Centonze, M., Saponaro, C. and Mangia, A. (2018) Nherf1 be-tween Promises and Hopes: Overview on Cancer and Prospective Openings. Translational Oncology, 11, 374-390. https://doi.org/10.1016/j.tranon.2018.01.006
|
[6]
|
Adamczyk, A., Niemiec, J., Janecka, A., et al. (2015) Prognostic Value of PIK3CA Mutation Status, PTEN and Androgen Receptor Expression for Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant Setting. Polish Journal of Pathology, 66, 133-141. https://doi.org/10.5114/pjp.2015.53009
|
[7]
|
Hsu, K.W., Huang, C.Y., Tam, K.W., et al. (2018) The Ap-plication of Non-Invasive Apoptosis Detection Sensor (NIADS) on Histone Deacetylation Inhibitor (HDACi)-Induced Breast Cancer Cell Death. International Journal of Molecular Sciences, 19, 452. https://doi.org/10.3390/ijms19020452
|
[8]
|
Lin, N.U., Vanderplas, A., Hughes, M.E., et al. (2012) Clinicopatho-logic Features, Patterns of Recurrence, and Survival among Women with Triple-Negative Breast Cancer in the National Comprehensive Cancer Network. Cancer, 118, 5463-5472. https://doi.org/10.1002/cncr.27581
|
[9]
|
Murria, R., Palanca, S., De Juan, I., et al. (2015) Immunohistochemical, Genetic and Epigenetic Profiles of Hereditary and Triple Negative Breast Cancers. Relevance in Personalized Medicine. American Journal of Cancer Research, 5, 2330-2343.
|
[10]
|
Hollenberg, S.M., Weinberger, C., Ong, E.S., et al. (1985) Primary Structure and Expression of a Functional Human Glucocorticoid Receptor cDNA. Nature, 318, 635-641. https://doi.org/10.1038/318635a0
|
[11]
|
Sullivan, W.P., Vroman, B.T., Bauer, V.J., et al. (1985) Isolation of Steroid Receptor Binding Protein from Chicken Oviduct and Production of Monoclonal Antibodies. Biochemistry, 24, 4214-4222. https://doi.org/10.1021/bi00336a060
|
[12]
|
Burdon, R.H. (1988) The Heat Shock Proteins. Endeavour, 12, 133-138.
https://doi.org/10.1016/0160-9327(88)90134-2
|
[13]
|
Jäättelä, M. (1999) Heat Shock Proteins as Cellular Lifeguards. Annals of Medicine, 31, 261-271.
https://doi.org/10.3109/07853899908995889
|
[14]
|
Sarker, D., Reid, A.H., Yap, T.A., et al. (2009) Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer. Clinical Cancer Research, 15, 4799-4805. https://doi.org/10.1158/1078-0432.CCR-08-0125
|
[15]
|
Thiebaut, C., Vlaeminck-Guillem, V., Tredan, O., et al. (2021) Non-Genomic Signaling of Steroid Receptors in Cancer. Molecular and Cellular Endocrinology, 538, Article ID: 111453. https://doi.org/10.1016/j.mce.2021.111453
|
[16]
|
Vrtačnik, P., Ostanek, B., Mencej-Bedrač, S., et al. (2014) The Many Faces of Estrogen Signaling. Biochemia Medica (Zagreb), 24, 329-342. https://doi.org/10.11613/BM.2014.035
|
[17]
|
Hickey, T.E., Selth, L.A., Chia, K.M., et al. (2021) The Androgen Re-ceptor Is a Tumor Suppressor in Estrogen Receptor-Positive Breast Cancer. Nature Medicine, 27, 310-320. https://doi.org/10.1038/s41591-020-01168-7
|
[18]
|
Rizza, P., Barone, I., Zito, D., et al. (2014) Estrogen Receptor beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines. Breast Cancer Research, 16, R21. https://doi.org/10.1186/bcr3619
|
[19]
|
Park, S., Koo, J.S., Kim, M.S., et al. (2011) Androgen Receptor Expression Is Significantly Associated with Better Outcomes in Estrogen Receptor-Positive Breast Cancers. Annals of Oncology, 22, 1755-1762.
https://doi.org/10.1093/annonc/mdq678
|
[20]
|
Okano, M., Oshi, M., Butash, A.L., et al. (2019) Estrogen Receptor Positive Breast Cancer with High Expression of Androgen Receptor has Less Cytolytic Activity and Worse Response to Neoadjuvant Chemotherapy but Better Survival. International Journal of Molecular Sciences, 20, 2655. https://doi.org/10.3390/ijms20112655
|
[21]
|
Park, S., Koo, J., Park, H.S., et al. (2010) Expression of Androgen Re-ceptors in Primary Breast Cancer. Annals of Oncology, 21, 488-492. https://doi.org/10.1093/annonc/mdp510
|
[22]
|
Witzel, I., Graeser, M., Karn, T., et al. (2013) Androgen Receptor Ex-pression Is a Predictive Marker in Chemotherapy-Treated Patients with Endocrine Receptor-Positive Primary Breast Cancers. Journal of Cancer Research and Clinical Oncology, 139, 809-816. https://doi.org/10.1007/s00432-013-1382-8
|
[23]
|
Aleskandarany, M.A., Abduljabbar, R., Ashankyty, I., et al. (2016) Prognostic Significance of Androgen Receptor Expression in Invasive Breast Cancer: Transcriptomic and Protein Expression Analysis. Breast Cancer Research and Treatment, 159, 215-227. https://doi.org/10.1007/s10549-016-3934-5
|
[24]
|
Hart, V., Gautrey, H., Kirby, J., et al. (2020) HER2 Splice Vari-ants in Breast Cancer: Investigating Their Impact on Diagnosis and Treatment Outcomes. Oncotarget, 11, 4338-4357. https://doi.org/10.18632/oncotarget.27789
|
[25]
|
Giovannelli, P., Di Donato, M., Galasso, G., et al. (2018) The An-drogen Receptor in Breast Cancer. Frontiers in Endocrinology (Lausanne), 9, 492. https://doi.org/10.3389/fendo.2018.00492
|
[26]
|
Ni, M., Chen, Y., Fei, T., et al. (2013) Amplitude Modulation of Androgen Signaling by c-MYC. Genes & Development, 27, 734-748. https://doi.org/10.1101/gad.209569.112
|
[27]
|
Venema, C.M., Bense, R.D., Steenbruggen, T.G., et al. (2019) Con-sideration of Breast Cancer Subtype in Targeting the Androgen Receptor. Pharmacology & Therapeutics, 200, 135-147.
https://doi.org/10.1016/j.pharmthera.2019.05.005
|
[28]
|
Shen, H., Yang, Y., Zhao, L., et al. (2016) Lin28A and An-drogen Receptor Expression in ER-/Her2+ Breast Cancer. Breast Cancer Research and Treatment, 156, 135-147. https://doi.org/10.1007/s10549-016-3744-9
|
[29]
|
Giovannelli, P., Di Donato, M., Auricchio, F., et al. (2019) An-drogens Induce Invasiveness of Triple Negative Breast Cancer Cells through AR/Src/PI3-K Complex Assembly. Scien-tific Reports, 9, Article No. 4490.
https://doi.org/10.1038/s41598-019-41016-4
|
[30]
|
Lehmann, B.D., Bauer, J.A., Schafer, J.M., et al. (2014) PIK3CA Mutations in Androgen Receptor-Positive Triple Negative Breast Cancer Confer Sensitivity to the Combination of PI3K and Androgen Receptor Inhibitors. Breast Cancer Research, 16, 406. https://doi.org/10.1186/s13058-014-0406-x
|
[31]
|
Choi, J.E., Kang, S.H., Lee, S.J., et al. (2015) Androgen Receptor Expression Predicts Decreased Survival in Early Stage Triple-Negative Breast Cancer. Annals of Surgical Oncology, 22, 82-89.
https://doi.org/10.1245/s10434-014-3984-z
|
[32]
|
Asano, Y., Kashiwagi, S., Onoda, N., et al. (2016) Clinical Veri-fication of Sensitivity to Preoperative Chemotherapy in Cases of Androgen Receptor-Expressing Positive Breast Cancer. British Journal of Cancer, 114, 14-20.
https://doi.org/10.1038/bjc.2015.434
|
[33]
|
Bozovic-Spasojevic, I., Zardavas, D., Brohée, S., et al. (2017) The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-Analysis of Clinical and Gene Expression Data. Clinical Cancer Research, 23, 2702-2712. https://doi.org/10.1158/1078-0432.CCR-16-0979
|
[34]
|
Vera-Badillo, F.E., Templeton, A.J., De Gouveia, P., et al. (2014) Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis. JNCI: Journal of the National Cancer Institute, 106, djt319. https://doi.org/10.1093/jnci/djt319
|
[35]
|
He, L., Du, Z., Xiong, X., et al. (2017) Targeting Androgen Receptor in Treating HER2 Positive Breast Cancer. Scientific Reports, 7, Article No. 14584. https://doi.org/10.1038/s41598-017-14607-2
|
[36]
|
Ni, M., Chen, Y., Lim, E., et al. (2011) Tar-geting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer. Cancer Cell, 20, 119-131. https://doi.org/10.1016/j.ccr.2011.05.026
|
[37]
|
Gucalp, A., Tolaney, S., Isakoff, S.J., et al. (2013) Phase II Trial of Bicalutamide in Patients with Androgen Receptor-Positive, Estrogen Receptor-Negative Metastatic Breast Cancer. Clini-cal Cancer Research, 19, 5505-5512.
https://doi.org/10.1158/1078-0432.CCR-12-3327
|
[38]
|
Traina, T.A., Miller, K., Yardley, D.A., et al. (2018) En-zalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical On-cology, 36, 884-890. https://doi.org/10.1200/JCO.2016.71.3495
|